Hybrid Satellite Symposium at the 49th Annual Meeting of the EBMT

Activity Overview

In this symposium, an expert panel will discuss cytomegalovirus (CMV) treatment guidelines and benefits and toxicities of traditional CMV therapies in hematopoietic cell transplant (HCT) patients. Panelists will address special challenges associated with refractory or drug-resistant CMV in HCT and present a new treatment option. An experienced patient with CMV will share impactful insights to help provide better care for HCT patients with CMV.

Hybrid Satellite Symposium, Attend in-person or virtually.
EBMT in Paris, France 

REGISTER TO ATTEND

Target Audience

Hematopoietic cell transplant (HCT) and hematology/oncology clinicians who manage CMV infection and disease in HCT patients.

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Select cytomegalovirus (CMV) treatment plans in hematopoietic cell transplantation (HCT) patients using evidence-based therapeutic approaches
  • Identify critical limitations to conventional CMV therapies that often result in suboptimal outcomes
  • Apply best practices for monitoring and treating HCT patients with resistant or refractory CMV

Activity Faculty

Chemaly 500x500

Roy F. Chemaly, MD, MPH, FACP, FIDSA, CMQ (Chair)

Professor, Medicine
Department of ID/IC/EH
Chief Infection Control Officer
Director, Clinical Virology Research Program
UT MD Anderson Cancer Center
Houston, United States

Rafael F. Duarte, MD, PhD, FRCP (Lon)

Rafael F. Duarte, MD, PhD, FRCP (Lon)

Head, Department of Hematology and Transplantation Programme
Hospital Universitario Puerta de Hierro Majadahonda
Profesor Asociado de Hematología
Universidad Autónoma de Madrid
Madrid, Spain

Prof. Sophie Alain, MD

Prof. Sophie Alain, MD

Professor, Virology
Limoges University Hospital
Research Leader, RESINFIT Inserm Team
Limoges University
Limoges, France

Provider Statement

This educational activity was independently developed by RMEI Medical Education, LLC.

Supporter Statement

This activity is supported by an educational grant from Takeda.

Subscribe

Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources